Mode
Text Size
Log in / Sign up
Phase 3 Completed N=258 Treatment

A Single-arm Study to Evaluate Safety and Effectiveness of VX-548 for Acute Pain

Source: ClinicalTrials.gov NCT05661734 ↗
Enrolled (actual)
258
Serious AEs
0.8%
Results posted
Jul 2025
Primary outcomePrimary: Safety and Tolerability as Assessed by Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) — 94; 2 Participants
◆ Published Evidence
Established
50citations · ~50 / year
Suzetrigine, a Non-Opioid Na<sub>V</sub>1.8 Inhibitor With Broad Applicability for Moderate-to-Severe Acute Pain: A Phase 3 Single-Arm Study for Surgical or Non-Surgical Acute Pain.
Journal of pain research · 2025 · Open access · Likely link

Summary

The purpose of this study is to evaluate the safety and effectiveness of VX-548 in treating acute pain.

Linked Publications (2)

  • Suzetrigine, a Non-Opioid Na<sub>V</sub>1.8 Inhibitor With Broad Applicability for Moderate-to-Severe Acute Pain: A Phase 3 Single-Arm Study for Surgical or Non-Surgical Acute Pain.
    Journal of pain research · 2025 · 50 citations · Open access · Likely link
  • The Clinical Application of Suzetrigine.
    Journal of pain & palliative care pharmacotherapy · 2026 · 1 citation · Likely link

Outcome Measures

OutcomeResultp-value
PRIMARY
Safety and Tolerability as Assessed by Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
94; 2
SECONDARY
Percentage of Participants Reporting Good, Very Good, or Excellent on a Patient Global Assessment (PGA) Scale
83.2

Eligibility Criteria

Key Inclusion Criteria

  • Body mass index (BMI) of greater than or equal to (≥) 18.0 to less than (<) 40.0 kilogram per meter square (kg/m^2)
  • Non-surgical participants with pain of new origin (not related to a prior known condition) that is moderate or severe on the verbal categorical rating scale (VRS) and ≥4 on the numeric pain rating scale (NPRS)
  • Surgical participants reporting pain at the surgical site that is moderate or severe on the VRS and ≥4 on the NPRS

Key Exclusion Criteria

  • Surgical participants:
  • History of previous surgery due to the same condition, except for procedures for which a previous surgery on the contra-lateral limb or organ is allowed
  • History of a prior surgical procedure in the same region of the body that resulted in any perioperative complications or that, in the opinion of the investigator or medical monitor, would preclude participation in the study
  • History of any illness or any clinical condition that, in the opinion of the investigator, might confound the results of the study or pose an additional risk in administering study drug to the participant

Other protocol defined Inclusion/Exclusion criteria may apply.

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT05661734) and the linked publication. Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.

Back to search